Analysis of correlation of CYR61 and MTHFR Gene Polymorphism in Legg-Calve-Perthes disease

Abstract:
Background:
Legg-Calve-Perthes disease (LCPD) is one of the most common causes of paediatric
femoral head osteonecrosis. Besides the other known etiological aspects, till
now genetic aspect has not been studied extensively. The present study was aimed
to find the association of genetic polymorphism of CYR61 and MTHFR gene with
the LCPD.
Materials
and Methods: Single
Nucleotide Polymorphisms (SNPs) analysis of the CYR61 and MTHFR genes in 41LCPDpatients
and 110 healthy controls were genotyped in this hospital-based study by polymerase
chain reaction and restriction fragment length polymorphism (PCR-RFLP).
Results:
The frequency of CYR61gene
homozygous mutant GG polymorphism was not significant in LCPD patients when
compared with controls.MTHFRC677T
homozygous mutant TT polymorphism was significant in LCPD patients as compared
to controls.
Conclusions:
The present
study showed a significant association of T allele of MTHFR C677T polymorphism with
LCPD and may be regarded as a risk factor to develop the LCPD in North Indian
patients.
References:
[1]
Bahmanyar S, Montgomery SM, Weiss RJ, Ekbom A. Maternal smoking during
pregnancy, other prenatal and perinatal factors, and the risk of
Legg-Calve-Perthes disease. Pediatrics.2008;122:e459- 464.
[2]
Boccia S, Hung R, Ricciardi G, Gianfagna F, Ebert MP, Fang JY, Gao CM, Gotze T,
Graziano F, Lacasaña-Navarro M, Lin D, Lopez-Carrillo L, Qiao YL, Shen H,
Stolzenberg-Solomon R, Takezaki T, Weng YR, Zhang FF, van Duijn CM, Boffetta P,
Taioli E. Meta- and pooled analyses of the methylenetetrahydrofolate reductase
C677T and A1298C polymorphisms and gastric cancer risk: a huge-GSEC review. Am
J Epidemiol.2008; 167: 505- 516.
[3]
Catterall A. Legg-calve Perthes syndrome. ClinorthopRelat Res 1981, 158:41-52
[4]
Campbell I G. Methylenetetrahydrofolate reductase polymorphism and susceptibility
to breast cancer. Breast Cancer Res. 2002; 14: 1-4.
[5]
Chung SM. The arterial supply of the developing proximal end of the human
femur. J Bone Joint Surg Am.1976;58:961- 970.
[6]
Chu X, Dong C, Lei R, Sun L, Wang Z, Dong Y, Shen M, Wang Y, Wang B, Zhang K,
Yang L, Li Y, Yuan W, Wang Y, Song H, Jin L, Xiong M, Huang W. Polymorphisms in
the interleukin 3 gene show strong association with susceptibility to Graves'
disease in Chinese population. Genes Immun.2009; 10: 260- 266.
[7] De Inocencio J. Epidemiology
of musculoskeletal pain in primary care. Arch
Dis Child.2004;89:431- 434.
[8]
Hall AJ, Barker DJ, Dangerfield PH, Taylor JF. Perthes’ disease of the hip in
Liverpool. Br Med J (Clin Res Ed).1983;287:1757- 1759.
[9]
Kim HK. Legg-Calve-Perthes disease: etiology, pathogenesis, and biology. J
PediatrOrthop.2011;31(2 suppl):S141- 146.
[10] Jandial S, Myers A, Wise E, Foster HE.
Doctors likely to encounter children with musculoskeletal complaints have low
confidence in their clinical skills. J Pediatr.2009;154:267-71.
[11]
Jeong MC, Navani A, Oksenberg JR. Limited allelic polymorphismin the human
interleukin-3 gene. Mol Cell Probes. 1998; 12: 49- 53.
[12] Joseph B, Varghese G, Mulpuri K,
NarasimhaRao K, Nair NS. Natural evolution of Perthes disease: a study of 610
children under 12 years of age at disease onset. J
PediatrOrthop.2003;23:590-600.
[13]
Joseph B, Willoughby R. Perthes' disease: a review of contributions from the
Asia-pacific region. Malays Orthop J. 2010;4: 1- 8.
[14]
Kim HK. Legg-Calve-Perthes disease. J Am AcadOrthopSurg.2010;18: 676- 686.
[15]
Kim HK, Morgan-Bagley S, Kostenuik P. RANKL inhibition: a novel strategy to
decrease femoral head deformity after ischemicosteonecrosis. J Bone Miner
Res.2006;21: 1946- 1954.
[16] Kim HK. Pathophysiology and new strategies for
the treatment of Legg-Calve-Perthes disease. J Bone Joint Surg Am.2012;94: 659-
669.
[17]
Lee ST, Vaidya SV, Song HR, Lee SH, Suh SW, Telang SS. Bone age delay patterns
in Legg-Calve-Perthes disease: an analysis using the Tanner and Whitehouse 3
method. J PediatrOrthop.2007;27:198-203.
[18] Lechner
A, Schutze N, Siggelkow H, Seufert J, Jakob F. The immediate early gene product
hCYR61 localizes to the secretory pathway in human osteoblasts. Bone. 2000
Jul;27(1):53-60.
[19]
Molloy MK, MacMahon B. Incidence of Legg-Perthes disease (osteochondritisde formans).
N Engl J Med 1966;275:988-90.
[20]
Nagase Y, Iwasawa M, Akiyama T, Kadono Y, Nakamura M, Oshima Y, Yasui T,
Matsumoto T, Hirose J, Nakamura H, Miyamoto T, Bouillet P, Nakamura K, Tanaka
S. Anti-apoptotic moleculeBcl-2 regulates the differentiation, activation, and
survival of bothosteoblasts and osteoclasts. J Biol Chem.2009;284: 36659-
36669.
[21]
Nelitz M, Lippacher S, Krauspe R, Reichel H.Perthes disease: current principles
of diagnosis and treatment. Dtsch Arztebl Int.2009;106:517- 523.
[22]
Park BL, Kim LH, Choi YH, Lee JH, Rhim T, Lee YM, Uh ST, Park HS, Choi BW, Hong
SJ, Park CS, Shin HD. Interleukin 3 (IL3)polymorphisms associated with
decreased risk of asthma and atopy. J Hum Genet. 2004; 49: 517- 527.
[23] Perry DC, Machin DM, Pope D, Bruce CE,
Dangerfield P, Platt MJ, et al. Racial and geographic factors in the incidence
of Legg-Calve-Perthes’ disease: a systematic review. Am
J Epidemiol.2012;175:159-66.
[24] Sanja
Srzentic, Gordana Nikcevic, Dusko Spasovski, Zoran Bascarevic, Zorica Zivkovic,
Zorica Terzic-Supic, Dragana Matanovic, Valentina Djordjevic, Sonja Pavlovic, Vesna
Spasovski. Predictive genetic markers of coagulation, inflammation and
apoptosis in Perthes disease-Serbian experience. Eur J Pediatr.2015; 174:
1085-1092.
[25]
Syed Rizwan Hussain ,Hena Naqvi , Syed Tasleem Raza, Faisal Ahmed, Sunil G.
Babu, Ashutosh Kumar, Zeashan Haider Zaidi, Farzana Mahdi.
Methylenetetrahydrofolate reductase C677T genetic polymorphisms and risk of
leukaemia among the North Indian population. Cancer Epidemiology.2012; 36:
227-231.
[26]
Tao L, Chen J, Zhou H, Qin C, Li P, Cao Q, Li J, Ju X, Zhu C, Wang M, Zhang Z,
Shao P, Yin C. A functional polymorphism in the CYR61 (IGFBP10) gene is
associated with prostate cancer risk. Prostate Cancer Prostatic Dis. 2013; 16:
95- 100.
[27]
Yamada R, Tanaka T, Unoki M, Nagai T, Sawada T, Ohnishi Y, Tsunoda T, Yukioka
M, Maeda A, Suzuki K, Tateishi H, Ochi T, Nakamura Y, Yamamoto K. Association
between a singlenucleotidepolymorphism in the promoter of the human
interleukin-3 gene and rheumatoid arthritis in Japanese patients, and
maximumlikelihoodestimation of combinatorial effect that two genetic locihave on susceptibility to the disease. Am J Hum Genet.2001;68:
674- 685.